| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (NCT07441681) | NRG Oncology | 2026-07-31 |
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) (NCT07554573) | NRG Oncology | 2026-06-30 |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma (NCT07452458) | NRG Oncology | 2026-06-08 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (NCT07166406) | NRG Oncology | 2026-02-26 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (NCT07097142) | NRG Oncology | 2025-10-07 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (NCT06958328) | NRG Oncology | 2025-08-21 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (NCT06532279) | NRG Oncology | 2025-06-23 |
| Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial (NCT06745024) | NRG Oncology | 2025-05-07 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (NCT06580314) | NRG Oncology | 2025-03-12 |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial (NCT06500481) | NRG Oncology | 2025-03-04 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain (NCT06500455) | NRG Oncology | 2024-12-12 |
| Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (NCT06279013) | NRG Oncology | 2024-10-14 |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors (NCT05896189) | NRG Oncology | 2024-02-29 |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (NCT05879926) | NRG Oncology | 2023-10-18 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer (NCT05624996) | NRG Oncology | 2023-07-12 |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (NCT05705401) | NRG Oncology | 2023-05-19 |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (NCT05408845) | NRG Oncology | 2023-03-03 |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial (NCT05327686) | NRG Oncology | 2023-02-01 |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (NCT05646316) | NRG Oncology | 2022-12-07 |
| Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases (NCT05438212) | NRG Oncology | 2022-10-24 |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (NCT05174169) | NRG Oncology | 2022-07-08 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (NCT05053152) | NRG Oncology | 2022-04-20 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (NCT05095376) | NRG Oncology | 2022-03-28 |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (NCT05080673) | NRG Oncology | 2022-02-09 |
| Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer (NCT05050162) | NRG Oncology | 2022-02-01 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (NCT05050084) | NRG Oncology | 2021-12-06 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049) | NRG Oncology | 2021-12-02 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (NCT04852887) | NRG Oncology | 2021-06-23 |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability (NCT04804644) | NRG Oncology | 2021-06-08 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (NCT04513717) | NRG Oncology | 2021-01-21 |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (NCT04251052) | NRG Oncology | 2020-09-01 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial (NCT04134260) | NRG Oncology | 2020-04-16 |
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma (NCT04105374) | NRG Oncology | 2020-01-31 |
| Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma (NCT04158141) | NRG Oncology | 2020-01-29 |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol (NCT03997370) | NRG Oncology | 2020-01-15 |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery (NCT04068103) | NRG Oncology | 2019-12-16 |
| Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring (NCT04037254) | NRG Oncology | 2019-10-08 |
| Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04095364) | NRG Oncology | 2019-09-20 |
| Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy (NCT03860961) | NRG Oncology | 2019-07-26 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (NCT03801876) | NRG Oncology | 2019-06-26 |
| Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial (NCT03371719) | NRG Oncology | 2018-06-20 |
| Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer (NCT03367702) | NRG Oncology | 2018-02-01 |
| Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer (NCT03186898) | NRG Oncology | 2018-01-26 |
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma (NCT03180502) | NRG Oncology | 2018-01-23 |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery (NCT03180268) | NRG Oncology | 2017-09-12 |